Tag: drug-eluting balloons
Enrolment completed in SAVE trial of Selution SLR for AVF treatment
MedAlliance has announced completion of patient enrolment in the SAVE clinical trial with the Selution Sustained Limus Release (SLR) 018 drug-eluting balloon (DEB) for...
First US patient enrolled in MedAlliance sirolimus DCB study
The first US patient has been enrolled in the SELUTION4SFA sirolimus drug-eluting balloon (DEB) study by Arthur Lee (Cardiac & Vascular Institute, Gainesville, USA)....
Cordis announces acquisition of MedAlliance
Cordis today announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance.
A press release notes that the agreement includes an...
MedAlliance receives third FDA breakthrough device designation for its sirolimus DEB...
MedAlliance, the first drug-eluting balloon (DEB) company in the world to receive US Food and Drug Administration (FDA) breakthrough device designation status for a...
Current status on drug-eluting devices in dialysis access
Dialysis access fistulae and grafts are life-saving in patients with renal insufficiency and failure. Numbers of patients requiring haemodialysis have continued to rise over...
